trial

High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms

NCTId NCT00403546
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 131 (actual)
Sponsored by Donald C. Goff, MD
Primary completion 2011-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
131 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-01
Primary completion
2011-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Ziprasidone

Sponsors

Donald C. Goff, MDLead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Collaborator

Investigators

1
Donald C. Goff, M.D.Principal Investigator

Sites

9 total
Augusta, United StatesFall River, United StatesGrand Rapids, United StatesAlbuquerque, United StatesBrooklyn, United StatesNew York, United StatesOrangeburg, United StatesButner, United StatesPlano, United States

Linked catalysts

1
High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Resid — primary completion2011-05

Facts & assertions

4 sourced
Enrollment
131
Phase
PHASE3
Primary Completion Date
2011-05
Status
COMPLETED
relationships
The graph out of here
drug
Ziprasidone
drug
lead_sponsor
Donald C. Goff, MD
company
collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Donald C. Goff, M.D.
person